Quanterix Balances Growth Optics With Underlying Weakness

Quanterix ((QTRX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Quanterix’s latest earnings call painted a cautiously optimistic picture, with strong reported growth masking real underlying pressures. Management highlighted 25% GAAP revenue growth, margin gains, and a solid cash cushion, but also acknowledged a 22% organic revenue drop and ongoing adjusted EBITDA losses. The tone balanced confidence in cost discipline and diagnostics milestones with realism about soft demand.

Robust Reported Q4 Growth Driven by Acquisitions

Total Q4 revenue reached $43.9 million, up 25% year over year and 7% sequentially, helped by acquired businesses and the release of pent‑up academic demand. While this headline growth looks impressive, it is partly a function of mix and M&A, making it less reflective of the core business’s true trajectory.

Diagnostics Partnerships Scale Up Rapidly

Quanterix now counts 25 diagnostics partnerships, which generated $9.6 million in 2025 versus $6.0 million a year earlier, a roughly 60% jump. This growing diagnostics base is becoming an increasingly important revenue pillar and could help diversify away from cyclically weak research funding.

LucentAD Hits Key Regulatory and Reimbursement Milestones

LucentAD, the company’s blood‑based Alzheimer’s test, secured a CMS reimbursement crosswalk with a reference price of $897, a significant validation step. A 510(k) submission was filed with the FDA in January 2026, and management expects a six‑ to nine‑month review window, framing the timeline for a broader commercial rollout.

Pipeline Momentum With New Assay Launches

Product innovation remained active, with 13 new assays launched in 2025, including two new Simoa Tau assays, pTau‑205 and pTau‑212, which have drawn strong early interest. Management signaled a steady cadence of additional assay launches each quarter through 2026, aimed at deepening recurring consumables usage.

Margin Expansion and Improving Non‑GAAP Economics

Fourth‑quarter GAAP gross margin came in at 45.7%, translating to $20.0 million of gross profit, while non‑GAAP gross margin reached 50% and $21.9 million in profit. Non‑GAAP operating expenses fell to $37.0 million, helping adjusted EBITDA improve to a loss of $7.9 million, a $4.0 million sequential step in the right direction.

Synergies and Cost Controls Take Hold

The company has implemented $74 million of its $85 million cost‑synergy plan and remains on track to complete the full target by the end of Q1. These savings are already visible in lower operating expenses and better cash usage, reinforcing management’s cost‑discipline narrative.

Cash Cushion Strengthens as Burn Rate Shrinks

Quanterix ended Q4 with $122 million in cash, equivalents, and marketable securities, giving it meaningful financial flexibility. Adjusted cash usage improved sharply to $3.0 million in the quarter from $16.1 million in Q3, supporting management’s aim to reach cash‑flow breakeven in the second half of 2026 and finish that year with about $100 million of cash and no debt.

Installed Base Growth Supports Recurring Revenues

Instrument placements remained solid, with 21 Simoa and 17 Spatial instruments placed in the quarter, up from 18 Simoa systems in the prior‑year period. Consumables revenue rose to $23.0 million, a $3.8 million sequential increase split between $15.4 million from Simoa and $7.6 million from Spatial, reinforcing the company’s recurring model.

Organic Revenue Contraction Highlights Demand Weakness

Beneath the reported growth, organic revenue fell 22% year over year in Q4, revealing meaningful softness in the core business. This decline underscores that acquisitions and mix effects are doing much of the work in sustaining top‑line expansion in the near term.

Simoa and Spatial Businesses Under Pressure

Simoa revenue was $27.0 million, reflecting a 22% organic decline, while Spatial revenue landed at $17.0 million, down 23% year over year. Excluding a now‑terminated diagnostics development agreement that contributed $2.5 million in the quarter, Spatial revenues still declined 16%, signaling broad‑based pressure across platforms.

Pharma Demand Softens, Weighing on Mix

Pharma‑related revenue dropped roughly 21% year over year, driven mainly by fewer large Accelerator projects versus 2024. This pullback in a typically higher‑margin customer segment not only dampened growth but also constrained profitability improvement.

Terminated Agreement Creates Near‑Term Revenue Headwind

Spatial revenues for 2025 included $5.6 million from a diagnostics development agreement that has since been terminated and was dilutive to financial results. While removing a low‑quality revenue stream should help margins, it also creates a noticeable top‑line headwind as the company recalibrates.

Elevated GAAP Opex Mask Underlying Progress

GAAP operating expenses were $44.8 million in Q4, inflated by about $6.4 million of acquisition, integration, restructuring, and purchase‑accounting costs plus $1.4 million in shipping costs. Management leaned on non‑GAAP adjustments to better reflect the underlying cost base and show that core expense trends are moving lower.

Adjusted EBITDA Loss Shows Profitability Still Out of Reach

Despite improvement, adjusted EBITDA remained negative at $7.9 million for the quarter, confirming the company is not yet profitable on an adjusted basis. Investors will be watching whether margin gains and cost synergies can bridge this gap as revenue growth remains subdued.

Academic Exposure Adds Cyclicality and Risk

Quanterix’s customer mix remains tilted toward academia, which represented roughly 55% of Q4 business, increasing exposure to constrained funding cycles. On a pro forma basis combining Quanterix and Akoya, academic revenue fell about 24% in Q4, highlighting a key structural challenge to near‑term growth.

Measured 2026 Outlook With Limited Top‑Line Upside

Management guided 2026 revenue to $169 million–$174 million, assuming no recovery in academic or pharma end markets and minimal impact from the terminated agreement. On a pro forma basis excluding that deal, this implies only around 2% revenue growth at the midpoint, paired with expected GAAP gross margins of 45%–49%, non‑GAAP margins of 49%–53%, and a path to cash‑flow breakeven in the back half of 2026, underpinned by the final $11 million in cost synergies.

Quanterix’s earnings call underscored a business in transition, with strong reported growth, disciplined cost control, and advancing diagnostics assets set against real demand headwinds and continued losses. For investors, the story now hinges on execution: stabilizing organic growth, capitalizing on LucentAD and other diagnostics opportunities, and delivering on the promised march to cash‑flow breakeven by 2026.